Recent Updates
Recently added Catalysts

MK0869, aprepitant

Phase 3

Major Depressive Disorder | Small molecule | Psychiatry |Merck & Company, Inc.|Last Updated: May 5, 2017

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindUNCONTROLLED
Total Trials4
Total Enrollment1,871

FDA Designations

No designations recorded

Clinical trial landscape

MK0869, aprepitant · 6 trials · 2 indications

Phase 3 6
NCT000902462 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)Postoperative Nausea and Vomiting
COMPLETED922 Analytics
NCT000901552 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED)Postoperative Nausea and Vomiting
COMPLETED805 Analytics
NCT00042029Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)Major Depressive Disorder
COMPLETED324 Analytics
NCT00034944Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)Major Depressive Disorder
COMPLETED495 Analytics
NCT00035295Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)Major Depressive Disorder
COMPLETED584 Analytics
NCT00035009Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)Major Depressive Disorder
COMPLETED468 Analytics
PHASE3COMPLETED
2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)
Postoperative Nausea and VomitingUnlock trial analytics
PHASE3COMPLETED
2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED)
Postoperative Nausea and VomitingUnlock trial analytics
PHASE3COMPLETED
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)
Major Depressive DisorderUnlock trial analytics
PHASE3COMPLETED
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)
Major Depressive DisorderUnlock trial analytics
PHASE3COMPLETED
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)
Major Depressive DisorderUnlock trial analytics
PHASE3COMPLETED
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)
Major Depressive DisorderUnlock trial analytics

Study Endpoints

Primary Endpoints

Prevention of PONV in the 24 hours following end of surgery; Tolerability
24 hours
HAMD-17 total score; Tolerability
HAMD-17 total score at week 8. Tolerability.
Change from baseline in HAMD-17 total score at week 8. Mk-0869 will be generally well tolerated

Secondary Endpoints

CGI-I Scale score; Sheehan Disability Scale
CGI-I Scale score at week 8 and at least a 50% reduction in the HAMD-17 total score.
CGI-I score at week 8, at least 50% reduction in the HAMD-17 total score, and Sheehan Disability Score at Week 8
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposePREVENTION

Interventions

NameTypeDescription
MK0869, aprepitantDRUG -
Comparator: ondansetron IVDRUG -
Comparator: placeboDRUG -
Comparator: paroxetine HCLDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Patient is at least 18 years of age. * Patient is scheduled to undergo open abdominal surgery requiring overnight hospital stay (24-hour hospital stay after end of surgery). * Patient is scheduled to receive general anesthesia. * Patient is scheduled to receive postoperative o...

Unlock Eligibility Criteria

Frequently asked questions about MK0869, aprepitant

What is MK0869 (aprepitant) used for?

MK0869, also known as aprepitant, is an investigational small molecule being studied for the treatment of nausea, postoperative nausea and vomiting, and major depressive disorder. It is in Phase 3 clinical development for these indications.

Who makes MK0869 (aprepitant)?

MK0869 (aprepitant) is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting Phase 3 clinical trials to evaluate the drug for major depressive disorder and other conditions.

What phase is MK0869 (aprepitant) in?

MK0869 (aprepitant) is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. All four completed trials were Phase 3 studies, and the drug is not currently in active trials.

What clinical trials is MK0869 (aprepitant) in?

MK0869 (aprepitant) has completed four Phase 3 clinical trials, including NCT00034944, NCT00035009, NCT00035295, and NCT00042029. These trials enrolled a total of 1,871 participants with major depressive disorder. All trials were randomized, double-blind, and uncontrolled.

Is MK0869 the same as aprepitant?

Yes, MK0869 is the same as aprepitant. The drug is referred to by both names in clinical trial records. It is being investigated for nausea, postoperative nausea and vomiting, and major depressive disorder.